News

Fierce Biotech2h
Prothena lays off 63% of employees in fallout from phase 3 amyloidosis drug fail
In May, the company announced the failure of the monoclonal antibody birtamimab to improve mortality in a phase 3 trial of ...
Fierce Biotech3h
Industry ‘deeply disappointed’ as FDA puts cell and gene therapy chief on administrative leave
The Alliance for Regenerative Medicine has voiced deep disappointment about reports that the FDA has put the director of its ...